Answers are grounded in this paper and cite their sources.
A series of novel S-β-D-acetylglucosides of double heterocyclic 1,2,3-thiadiazole and 1,2,4-triazole compounds(6a~6d) was synthesized from substituted 1,2,3-thiadiazoles. The structures of target compounds were confirmed by 1H NMR, 13C NMR and IR spectroscopy. The antimicrobial activities of S-glucoside Schiff base and its corresponding reduced structure were compared emphatically. The data of in vitro antimicrobial activities show that most of the tested compounds display good antimicrobial activities against Staphylococcus aureus(S.a.)(ATCC 6538), Escherichia coli(E.c.)(ATCC 8099) as well as Monilia albican(M.a.)(ATCC 10231). The antimicrobial activities of S-glucoside Schiff base are better than that of the corresponding reduced structures. Especially, compound 5d show stronger antibacterial activities than others, and the minimum value of MIC to 5d is better than that of fluconazole. The minimum values of MIC to all target compounds against S.a. are less than or equal to 32 mg/L.
No takes yet. Share an insight, caveat, or question.
A 2014 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: